Log in with your email address username.


[Comment] A positive randomised trial in cutaneous T-cell lymphoma

The discovery that CD30 (Ki-1, TNFRSF8), a membrane protein belonging to the tumour necrosis factor receptor superfamily, is uniformly expressed in anaplastic large-cell lymphoma was instrumental in defining CD30-positive T-cell lymphoproliferative disorders.1 Less homogeneous expression of CD30 was also reported in cutaneous T-cell lymphoma, particularly in tumour-stage mycosis fungoides with large-cell transformation.2 Attempts to therapeutically target CD30 with SGN-30 (cAC10), a so-called naked chimeric anti-CD30 monoclonal antibody, were disappointing,3 with the exception of a small study4 in cutaneous T-cell lymphoma, which showed 16 (70%) of 23 patients achieving an overall response, with some durable complete responses.